Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution

Neuraminidase inhibitors (NAIs) are the only available licensed therapeutics against human H7N9 influenza virus infections. The emergence of NAI-resistant variants of H7N9viruses with an NA R292K mutation poses a therapeutic challenge. A comprehensive understanding of the susceptibility of these vir...

Full description

Bibliographic Details

Published in:	Emerging Microbes and Infections
Main Authors:	Xiaonan Zhang, Zhigang Song, Jing He, Hui-Ling Yen, Jianhua Li, Zhaoqin Zhu, Di Tian, Wei Wang, Lei Xu, Wencai Guan, Yi Liu, Sen Wang, Bisheng Shi, Wanju Zhang, Boyin Qin, Jialin Cai, Yanmin Wan, Chunhua Xu, Xiaonan Ren, Haili Chen, Lu Liu, Yuqin Yang, Xiaohui Zhou, Wenjiang Zhou, Jianqing Xu, Xiaoyan Zhang, Malik Peiris, Yunwen Hu, Zhenghong Yuan
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2014-01-01
Subjects:	H7N9 influenza virus neuraminidase oseltamivir peramivir
Online Access:	https://www.tandfonline.com/doi/10.1038/emi.2014.80